Recruiting
Squamous cell carcinoma of head and neck
RecruitingStudy of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases
Registered drugNo placebo
Study of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases
Registered drugNo placebo
- Disease:Squamous cell carcinoma of head and neck
- Substances:CarboplatinCisplatin+5
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:Carboplatin
